Gilead Sciences : 2025 EFPIA Disclosure code – Self-Certification letter (gilead 2025 disclosure code self certification letter)

Published: 2025-06-02 06:45:05 ET GILD

Published on 06/02/2025 at 06:45

Healthcare professionals (HCPs) and healthcare organisations (HCOs) with whom Gilead Sciences works provide the pharmaceutical industry with valuable, independent and expert knowledge derived from their clinical and management experience. As owners of scientific knowledge and experts in medicinal products, pharmaceutical companies can be a unique resource to the healthcare systems and providers, which will ultimately benefit the patients.

In the same way, the pharmaceutical industry works with Patient Organisations (POs), this collaboration is essential in addressing patient needs. POs have a key role in helping to shape, develop and define the outcomes that make the most difference to patients.

EFPIA and its member associations have adopted codes and guidelines to ensure that the interactions of their member companies with HCPs, HCOs and POs meet the high standards of integrity and transparency. Building greater transparency to the relationships between pharmaceutical companies and HCPs/HCOs/POs aims to building understanding of the collaboration and recognition of its value to patient care.

Except in countries where disclosure is prescribed by laws, Gilead Sciences hereby confirms that its disclosures of transfers of value (ToVs) to HCPs, HCOs and POs made in 2023 have been reported in application of the EFPIA Code following key principles:

Gilead Sciences certifies that:

Its disclosures are made in each country covered by the EFPIA Code where it operates;

Its disclosures include direct and indirect ToVs, as defined in the Code and associated guidance issued by EFPIA;

Its Methodological Note describes the process it has followed in order to compile the data hereby disclosed.

Gilead Sciences certifies that:

Data collection complies with the requirements of the EFPIA Code;

Actions are taken to ensure individual disclosure for HCPs and HCOs' transfers of values (each as defined in the EFPIA Code).

Gilead Sciences certifies that aggregate disclosure is limited to the following topics:

Research and Development Transfers of Value (as defined in the EFPIA Code);

Transfers of Value to Recipients that have opposed to the publication on grounds of the protection of their private data;

If an HCP or HCO (where applicable) has provided consent to individual disclosure only in respect of part of the Transfers of Value he/she/it received, all Transfers of Value to such HCP or HCO (where applicable) are being disclosed in the aggregate.

Gilead Sciences certifies that its disclosure complies with the Data Privacy obligations.

Date:

May 26, 2025 | 7:08:45 AM PDT

Name of signatory: Josephine Comiskey

Position in the Company: Senior Vice President, ACE Region Signature:

Disclaimer

Gilead Sciences Inc. published this content on June 02, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on June 02, 2025 at 10:44 UTC.